MDLN · XBRL financial data
Medline financial statements, every quarter
The same tables from 3 filings, lined up. Matched by XBRL tag: renamed lines keep their history.
How these numbers work
- Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
- Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
- * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
- 0 means a filing states zero; a dash (—) means no filing states that number.
- “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
- Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
- Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
- Shares outstanding come from each filing's cover page, as of the date printed there.
- Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.
Income statement
CSVFiscal quarters (MDLN's year ends in late December)
| In millions of dollars | Dec 31, 2025 | Mar 28, 2026 | Jun 27, 2026 |
|---|---|---|---|
| Revenue | year only | 7,352 | 7,685 |
| Cost of goods and services sold | year only | 5,511 | 5,470 |
| Gross profit | year only | 1,841 | 2,215 |
| Research and development | year only | — | — |
| Selling, general and administrative | year only | 1,228 | 1,295 |
| Total operating expenses | year only | 1,419 | 1,820 |
| Other operating income (expense) | year only | (15) | (348) |
| Operating income (loss) | year only | 422 | 395 |
| Interest income | year only | 29 | 49 |
| Interest expense | year only | 165 | 168 |
| Other income (expense) | year only | 1 | (42) |
| Income tax expense (benefit) | year only | 52 | 96 |
| Net income (loss) | year only | — | — |
| Earnings per share, basic USD per share | — | 0.16 | 0.07 |
| Earnings per share, diluted USD per share | — | 0.16 | 0.07 |
| Weighted average shares, basic millions of shares | — | 819 | 857 |
| Weighted average shares, diluted millions of shares | — | 825 | 861 |
Balance sheet
CSVFiscal quarters (MDLN's year ends in late December)
| In millions of dollars | Dec 31, 2025 | Mar 28, 2026 | Jun 27, 2026 |
|---|---|---|---|
| Cash and cash equivalents | 1,939 | 2,236 | 2,327 |
| Short-term investments | 0 | — | 350 |
| Accounts receivable | 3,533 | 3,674 | 3,661 |
| Inventory | 4,769 | 4,807 | 4,665 |
| Total current assets | 10,679 | 11,180 | 11,742 |
| Property and equipment, net | 4,778 | 4,758 | 4,697 |
| Right-of-use asset | 432 | — | — |
| Goodwill | 8,079 | 8,076 | 8,072 |
| Total assets | 38,484 | 39,014 | 39,350 |
| Accounts payable | 961 | 932 | 1,043 |
| Accrued liabilities | 1,452 | 1,527 | 1,638 |
| Current portion of long-term debt | 76 | 76 | 28 |
| Total current liabilities | 2,490 | 2,536 | 2,710 |
| Long-term debt | 12,484 | 12,495 | 12,548 |
| Lease liability, non-current | 386 | — | — |
| Total liabilities | 19,198 | 19,665 | 20,273 |
| Retained earnings (accumulated deficit) | (7) | 122 | 182 |
| Total stockholders' equity | 10,737 | 11,272 | 11,572 |
| Total liabilities and equity | 38,484 | 39,014 | 39,350 |
Cash flows
CSVFiscal quarters (MDLN's year ends in late December)
| In millions of dollars | Dec 31, 2025 | Mar 28, 2026 | Jun 27, 2026 |
|---|---|---|---|
| Net income (loss) | year only | — | — |
| Stock-based compensation | year only | 23 | 29* |
| Depreciation and amortization | year only | 254 | 256* |
| Net cash from operating activities | year only | 412 | 715* |
| Purchases of property and equipment | year only | 96 | 111* |
| Net cash from investing activities | year only | (96) | (461)* |
| Share repurchases | year only | 0 | 0* |
| Net cash from financing activities | year only | (13) | (159)* |
| Net change in cash | year only | 296 | 91* |
Compare with peers
SIC 3841 and related industry codes, similar size. Each row is the latest quarter reported.
How peers are chosen
- SIC 3841 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
- Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
- * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
| Company | Cash ($M) | Revenue, quarter ($M) | Operating cash flow, quarter ($M) | Shares outstanding | Quarter |
|---|---|---|---|---|---|
| Medline | 2,327 | 7,685 | 715* | not reported | 10-QJun 27, 2026 |
| Solventum | 403 | 2,209 | 227* | 170.2M | 10-QJun 30, 2026 |
| Hologic | 2,168 | 1,048 | 230 | 223.2M | 10-QDec 27, 2025 |
| Align Technology | 1,103 | 1,056 | 193* | 71.0M | 10-QJun 30, 2026 |
| West Pharmaceutical Services | 464 | 875 | 190* | 69.7M | 10-QSep 30, 2026 |
| Baxter International | 1,975 | 2,976 | 558* | 517.3M | 10-QSep 30, 2026 |
| Penumbra | 254 | 410 | 42* | 39.4M | 10-QSep 30, 2026 |
| Zimmer Biomet Holdings | 410 | 2,177 | 448* | 190.7M | 10-QJun 30, 2026 |
| Insulet | 535 | 802 | 88* | 69.4M | 10-QJun 30, 2026 |
Not investment advice. Not affiliated with the U.S. SEC.